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Abstract 17 
Dipeptidyl peptidase IV (DPP-IV) inhibitory peptides were identified in silico within camel milk 18 
proteins. Camel milk was hydrolysed with trypsin using a design of experiments (DOE, 19 
temperature (40-60°C), enzyme to substrate (E:S) ratio (0.50-2.00% (w/w)) and time (60-240 20 
min)). Fifteen hydrolysates (H1-H15) having DPP-IV half maximal inhibitory concentration 21 
(IC50) values between 0.52  0.06 (H9) and 1.26  0.13 (H1) mg mL
-1 
were produced. Camel and 22 
bovine milk proteins hydrolysed at 40C, 1.8% E:S and 218 min had DPP-IV IC50 values of 0.68 23 
± 0.08 and 0.85 ± 0.10 mg mL
-1
 (p < 0.05), respectively. Potent and unique DPP-IV inhibitory 24 
peptides (Leu-Pro-Val-Pro-Gln and Trp-Lys) were identified in camel milk protein hydrolysates, 25 
which were not present in bovine milk protein hydrolysates. The DPP-IV inhibitory properties of 26 
camel milk peptides were reported for the first time in this study. Camel milk is an interesting 27 
substrate to further investigate for its antidiabetic potential. 28 
 29 
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1 Introduction 33 
Bovine milk proteins appear to be the most studied substrate for the generation of bioactive 34 
peptides. However, proteins from other species (i.e., goat, donkey, mare, yak and buffalo) have 35 
also been investigated for their ability to generate bioactive peptides (Anusha & Bindhu, 2016). 36 
The bioactive properties of camel (Camelus dromedarius) milk protein derived-peptides do not 37 
appear to have been extensively studied. However, camel milk, which contains antibodies and 38 
immunologically active components (i.e., lactoferrin, lactoperoxidase and lysozyme), has 39 
traditionally been utilised for its medicinal properties targeted to a range of metabolic and 40 
autoimmune diseases (for review, see: Dubey, Lal, Mittal, & Kapur, 2016). Due to its content in 41 
insulin and insulin-like components, camel milk has been proposed as an adjunct in the therapy 42 
for type 1 diabetes. Human intervention studies with type 1 diabetes sufferers have demonstrated 43 
that consumption of camel milk allowed for a significant reduction in insulin dose while still 44 
achieving glycaemic control (Agarwal et al., 2003; Agrawal, Jain, Shah, Chopra, & Agarwal, 45 
2011). 46 
The composition of camel milk proteins has been well studied. Camel milk lacks -lactoglobulin 47 
(-Lg) and is richer in -casein (CN), -lactalbumin (-La) and serum albumin than bovine milk 48 
(El-Agamy, 2009; Hailu et al., 2016). A wide range of bioactivities including antihypertensive, 49 
antioxidant, antimicrobial, anti-inflammatory and immunomodulatory properties have been 50 
reported in the literature for camel milk protein-derived peptides (for reviews, see: Hailu et al., 51 
2016; Mati et al., 2016). More particularly, the antioxidant, antimicrobial and angiotensin 52 
converting enzyme (ACE) inhibitory activities of camel milk protein hydrolysates appear to have 53 
been studied (Jrad et al., 2014; Kumar, Chatli, Singh, Mehta, & Kumar, 2016; Moslehishad et 54 
al., 2013; Rahimi et al., 2016; Salami et al., 2010). In certain instances more potent bioactivities 55 
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(antimicrobial, ACE inhibition and antioxidant activity) have been reported for camel compared 56 
to bovine milk hydrolysates and fermentates (Moslehishad et al., 2013; Salami et al., 2010). 57 
The inhibition of dipeptidyl peptidase IV (DPP-IV), a metabolic enzyme involved in the 58 
cleavage of incretins (i.e., gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 59 
(GLP-1)), is a target for antidiabetic drugs. CN hydrolysates from various species (bovine and 60 
caprine) display DPP-IV inhibitory properties in vitro (Zhang et al., 2016). An earlier in silico 61 
study predicted that bovine, caprine and ovine -Lg had the same DPP-IV inhibitory potential. 62 
This was based on the presence of the same known DPP-IV inhibitory peptides across the three 63 
milk species, which was explained by the high level of conservation between their -Lg 64 
sequences (Tulipano, Cocchi, & Caroli, 2012). To our knowledge, camel proteins have never 65 
been studied for their ability to release DPP-IV inhibitory peptides. 66 
The aim of this study was to demonstrate that camel milk proteins could yield DPP-IV inhibitory 67 
peptides upon digestion with trypsin. A design of experiments (DOE) was used to optimise the 68 
release of DPP-IV inhibitory peptides from camel milk proteins during enzymatic hydrolysis. 69 
The hydrolysates generated were characterised from a physicochemical perspective (degree of 70 
hydrolysis (DH), molecular mass distribution and peptide profile). In vitro simulated digestion of 71 
the hydrolysates was used to study stability of their DPP-IV inhibitory properties to digestive 72 
enzymes. Peptide identification was also performed using liquid chromatography-tandem mass 73 
spectrometry (LC-MS/MS). 74 
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2 Materials and Methods 75 
2.1 Reagents 76 
Hydrochloric acid (HCl), sodium hydroxide (NaOH), high performance liquid chromatography 77 
(HPLC) grade water and acetonitrile were from VWR (Dublin, Ireland). Sodium phosphate 78 
monobasic, sodium phosphate dibasic, sodium dodecyl sulphate (SDS), trifluoroacetic acid 79 
(TFA), tris(hydroxymethyl)aminomethane (TRIS), Gly-Pro-pNA, Leu, diprotin A (Ile-Pro-Ile), 80 
porcine DPP-IV (≥ 10 units mg-1 protein), standards for molecular mass distribution (i.e., bovine 81 
serum albumin (BSA), β-Lg, -La, aprotinin, bacitracin, Leu-Trp-Met-Arg and Asp-Glu), mass 82 
spectrometry (MS) grade water and acetonitrile were purchased from Sigma-Aldrich (Dublin, 83 
Ireland). A micro bicinchoninic acid (BCA) protein assay kit and 2,4,6-trinitrobenzenesulfonic 84 
acid (TNBS) from Pierce Biotechnology were obtained from Medical Supply Company (Dublin, 85 
Ireland). Synthetic peptides used for MS confirmatory studies were purchased from Sigma-86 
Aldrich (His-Leu and Phe-Leu), Thermo Fisher Scientific (Ulm, Germany; Ile-Ile, Ile-Leu, Leu-87 
Ile, Leu-Leu, Leu-Pro-Leu, Trp-Gln, Trp-Ile and Val-Pro), Bachem (Bubendorf, Switzerland; 88 
Ala-Leu, Glu-Lys, Trp-Leu, Trp-Lys, Trp-Tyr, Tyr-Ile, Tyr-Leu, Tyr-Pro and Ser-Leu) and 89 
Genscript (Piscataway, NJ, USA; Phe-Phe and Pro-Pro). Trypsin PTN 6.0S was provided by 90 
Novozymes (Bagsvaerd, Denmark), pepsin by Biocatalysts (Cefn, UK, Wales) and Corolase PP 91 
by AB enzymes (Darmstadt, Germany). Milk protein isolate (MPI, 86% (w/w) protein) was 92 
obtained from Kerry Ingredients (Listowel, Ireland). 93 
 94 
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2.2 In silico analysis of camel milk proteins 95 
The sequences of major bovine and camel milk proteins (αs1-, αs2-, β- and κ-CN as well as β-Lg 96 
and α-La) were obtained from UniProt on the ExPASy resource portal. The DPP-IV inhibitory 97 
potential of each protein was determined in silico using the model described in Nongonierma and 98 
FitzGerald (2014a). This model takes into account the protein coverage (PC) of known DPP-IV 99 
inhibitory peptides having a half maximal inhibitory concentration (IC50) < 2000 µM. The PC 100 
was subsequently corrected (PCcorrected) to incorporate in the in silico model the most potent and 101 
non-overlapping DPP-IV inhibitory peptides in the protein sequence. This approach allowed 102 
calculation of a DPP-IV inhibitory potency index (PI) which incorporates the DPP-IV IC50 value 103 
of the peptides and the molecular mass of the protein (Nongonierma & FitzGerald, 2014a). 104 
2.3 Enzymatic hydrolysis of camel milk proteins 105 
Skimmed freeze-dried milk obtained from the raw milk of one-humped dromedary Arabian 106 
camels (Camelus dromedarius) was procured from the Al Ain Dairy farm (Al Ain, United Arab 107 
Emirates (UAE)). The protein content of the freeze-dried camel milk powder was determined in 108 
triplicate (n=3) using the BCA method as previously described (Nongonierma, Le Maux, 109 
Dubrulle, Barre, & FitzGerald, 2015). 110 
A DOE was employed to hydrolyse camel milk proteins as previously described (Nongonierma, 111 
Mazzocchi, Paolella, & FitzGerald, 2017). Fifteen hydrolysates (H1-H15, Table 1) were 112 
generated using the variation of three parameters, i.e., temperature (40, 50 and 60°C), E:S (0.50, 113 
1.25 and 2.00% (w/w)) and hydrolysis time (60, 150 and 240 min) which were evaluated at three 114 
(-1, 0 and +1 centred and reduced (z-centred) values, respectively) different levels (Table 1). 115 
Hydrolysates H1-H11 and H13-H15 were generated once while the central point hydrolysate 116 
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(H12) was generated as three independent hydrolysates (n=3, H12A, H12B and H12C) for 117 
assessment of reproducibility purposes. 118 
Camel milk protein hydrolysis was carried out using trypsin as described earlier (Nongonierma, 119 
Le Maux, Esteveny, & FitzGerald, 2017). Briefly, camel milk (2.5% (w protein/w)) was 120 
resuspended in distilled water and incubated for 60 min in a water bath (Lauda E100, Lauda 121 
Brinkmann, Lauda-Königshofen, Germany) set at 50C. Subsequently, the pH was adjusted to 122 
7.0 using 2 M NaOH. Temperature, E:S and hydrolysis time were as defined by the DOE (Table 123 
1). At the end of each reaction, the enzyme was heat inactivated (90°C, 20 min) in a water bath. 124 
A control sample (unhydrolysed camel milk) without enzyme addition was prepared by 125 
incubation for 240 min at each hydrolysis temperature. 126 
A specific combination of temperature, E:S and hydrolysis time within the boundaries of the 127 
DOE was predicted (section 2.5.) to yield a camel milk protein hydrolysate with a low DPP-IV 128 
IC50 value. These conditions were used to generate three independent replicate camel milk 129 
protein hydrolysates (H16A, H16B and H16C). For comparative purposes, bovine MPI was also 130 
hydrolysed in triplicate (H17A, H17B and H17C) using the same hydrolysis conditions. All 131 
samples were freeze-dried (FreeZone 18L, Labconco, Kansas City, MO, USA) and stored at -132 
20°C until utilisation. 133 
2.4 DH determination using the TNBS assay 134 
The DH of the hydrolysates (H1-H17) was determined in triplicate (n=3) using the TNBS 135 
method (Adler-Nissen, 1986) as per Le Maux, Nongonierma, Barre, and FitzGerald (2016). 136 
Absorbance values (350 nm) were measured with a microplate reader (Biotek Synergy HT). DH 137 
was calculated using Equation 1: 138 
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DH = 100 ×
(AN2−AN1)
N𝑝𝑏 
        (Equation 1) 139 
 140 
With AN1, the amino nitrogen content of the unhydrolysed protein (mg g
-1
 protein); AN2, the 141 
amino nitrogen content of the hydrolysate (mg g
-1
 protein) and Npb, the nitrogen content of the 142 
peptide bonds in the protein substrate (114.34 mg g
-1
 protein). 143 
2.5 Response surface methodology (RSM) and prediction of optimum hydrolysis 144 
conditions 145 
RSM curves were generated as described earlier (Nongonierma, Mazzocchi, et al., 2017) using a 146 
multilinear regression (MLR) model (Equation 2, complete model) with Matlab (version 147 
R2015b, MathWorks, Inc, Natick, MA, USA). 148 
𝑌 = 𝛽0 + 𝛽1𝑇 + 𝛽2𝐸𝑆 + 𝛽3𝑡 + 𝛽4𝑇
2 + 𝛽5𝐸𝑆
2 + 𝛽6𝑡
2 +  𝛽7 𝑇 × 𝐸𝑆 +  𝛽8𝑇 ×  𝑡 + 𝛽9𝐸𝑆 ×  𝑡 +  𝜀   (Equation 2) 149 
With Y, the DPP-IV IC50 value; β0 to β9: the coefficients of the MLR model; T (temperature), ES 150 
(enzyme to substrate ratio) and t (time): the z-centred parameters of the experimental design and 151 
ε: the residual of the model. 152 
The complete model (Equation 2) was simplified (simplified model) by only taking into account 153 
the main parameters (T, ES and t) and their interactions having a p-value  0.1 (Contreras, 154 
Hernández-Ledesma, Amigo, Martín-Álvarez, & Recio, 2011). Hydrolysis parameters yielding 155 
low DPP-IV IC50 values were determined (van der Ven, Gruppen, de Bont, & Voragen, 2002). 156 
2.6 In vitro simulated gastrointestinal digestion (SGID) of intact and hydrolysed camel 157 
milk proteins 158 
In vitro SGID was conducted with camel milk and H9 as described earlier (Walsh et al., 2004). 159 
Briefly, samples were resuspended in distilled water to 2% (w protein equivalent/w) for 30 min 160 
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at 37°C and the pH was adjusted to 2.0 using 1 N HCl. Hydrolysis with pepsin (E:S 2.5% (w/w)) 161 
was carried out under pH regulation (2.0) with HCl (pH stat Titrando 843, Tiamo 1.4 Metrohm, 162 
Dublin, Ireland) for 90 min at 37°C. Pepsin was then heat inactivated (90°C, 20 min). An aliquot 163 
of the peptic hydrolysate was brought to pH 7.5 using 1 M NaOH and then hydrolysed with 164 
Corolase PP (E:S 1% (w/w)) for 150 min at 37°C, pH 7.5 using a pH stat (Metrohm), to yield 165 
SGID_CM or SGID_H9 for camel milk and H9, respectively. The reaction was terminated by 166 
thermal treatment (90°C, 20 min). Samples were freeze-dried and stored at -20°C until 167 
utilisation. 168 
2.7 DPP-IV inhibitory assay 169 
The DPP-IV inhibition assay was carried out in triplicate as outlined earlier (Nongonierma & 170 
FitzGerald, 2013a). The freeze-dried samples were dispersed in HPLC water at concentrations 171 
ranging from 2.5 × 10
-2
 to 2.5 mg mL
-1
 (final concentration expressed in mg protein equivalent 172 
mL
-1
) and Diprotin A, the positive control at final concentrations ranging from 12.5 × 10
-2
 and 173 
12.5 µg mL
-1
. Essentially, 25L of sample was pipetted onto a 96-well microplate (Sarstedt, 174 
Dublin, Ireland) containing the reaction substrate, Gly-Pro-pNA (final concentration 0.200 mM). 175 
The reaction was initiated by the addition of DPP-IV (final concentration 0.0025 units mL
-1
). All 176 
reagents were diluted in 100 mM Tris-HCl buffer pH 8.0. The negative control consisted of 100 177 
mM Tris-HCl buffer pH 8.0 and Gly-Pro-pNA. The microplate was incubated at 37C for 60 min 178 
in a microplate reader (Biotek Synergy HT, Winoosky, VT, USA) and absorbance of the pNA 179 
released was monitored at 405 nm. The DPP-IV IC50 values were determined by plotting the 180 
percentage inhibition as a function of the test compound concentration. 181 
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2.8 Peptide profile by reverse-phase ultra-performance liquid chromatography (RP-182 
UPLC) and molecular mass distribution by gel permeation high performance liquid 183 
chromatography (GP-HPLC) 184 
Peptide profiles were determined by RP-UPLC (UPLC Acquity - Waters, Milford, MA, USA) as 185 
described previously (Nongonierma & FitzGerald, 2012). Briefly, samples (milk and 186 
hydrolysates) were resuspended (0.2% w protein equivalent/v) in solvent A (0.1% (v/v) TFA in 187 
MS grade water) and filtered with 0.2 µm cellulose acetate filters (VWR). Peptide/protein 188 
separation was carried out at 30°C with a flow rate of 0.3 mL min
-1
 and an injection volume of 189 
10 µL. An Acquity UPLC BEH C18, 130 Å column (2.1 mm  50 mm  1.7 µm), equipped with 190 
an Acquity BEH C18 (1.7 µm) vanguard pre-column (both from Waters), was used. Peptides and 191 
proteins were eluted using a linear gradient: 0-0.28 min: 100% A; 0.28-60 min: 100-40% A, with 192 
solvent B consisting of 0.1% (v/v) TFA and 80% MS grade acetonitrile in water. Absorbance 193 
was monitored at 214 nm. 194 
Molecular mass distribution profiles were determined by GP-HPLC as described earlier 195 
(Spellman, O’Cuinn, & FitzGerald, 2009). An HPLC system (Waters model 600 binary pump, 196 
model 2707 autosampler and model 2489 dual λ absorbance detector) was employed to analyse 197 
samples. Separation of compounds was conducted in isocratic mode at 21°C with a TSK G2000 198 
SW separating column (600×7.5 mm ID - Tosoh Bioscience, Tokyo, Japan) connected to a 199 
TSKGEL SW guard column (75×7.5 mm ID - Tosoh Bioscience) with a mobile phase consisting 200 
of 0.1% (v/v) TFA and 30% HPLC grade acetonitrile in HPLC water. The flow rate was of 0.5 201 
mL min
-1
 for 60 min. A volume of 20 µL sample (0.2% (w protein equivalent/v) in mobile phase 202 
filtered through 0.2 µm PTFE syringe filters (VWR)) was injected. The absorbance was 203 
monitored at 214 nm. The molecular mass standards consisted of BSA, β-Lg, -La, aprotinin, 204 
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bacitracin, Leu-Trp-Met-Arg and Asp-Glu. The molecular mass distribution of compounds > 10, 205 
10-5, 5-1 and < 1 kDa was determined. 206 
2.9 Peptide identification by LC-MS/MS 207 
Peptide identification in H9, H16, H17, SGID_H9 and SGID_CM milk was performed using LC-208 
MS/MS as described previously (Norris, Poyarkov, O’Keeffe, & FitzGerald, 2014; O’Keeffe & 209 
FitzGerald, 2015). An ultra-HPLC (UHPLC) UltiMate 3000 (Dionex, Camberley, Surrey, UK) 210 
fitted with an Aeris Peptide XB-C18 column (150  2.1 mm, 1.7 μm, Phenomenex, Cheshire, 211 
UK) was used. The UPLC was coupled to a quadrupole time-of-flight mass spectrometer (Q-212 
TOF, Impact HD™, Bruker Daltonics GmbH, Bremen, Germany) using a 50-600 and 50-2500 213 
m/z acquisition range. The MS was fitted with an electrospray ionisation (ESI) source used in 214 
positive ion mode. Data acquisition was performed with Hystar software (Bruker Daltonics). 215 
Samples were resuspended in mobile phase A (0.1% formic acid in MS water) to a final 216 
concentration of 0.1 g L
-1 
and filtered wirth Minisart® RC15 made of hydrophilic regenerated 217 
cellulose (Sartorius, Goettingen, Germany). A sample volume of 5 (for ions ranging from 50-218 
2500 m/z) and 10 µL (for ions ranging from 50-600 m/z) was injected. Peptide identification was 219 
carried out with PEAKS Studio (version 7.5, Bioinformatics Solutions Inc, Waterloo, Canada). 220 
The false discovery rate (FDR), average local confidence (ALC) and MS/MS tolerance were set 221 
at 1, 60% and 0.1 Da, respectively. In addition, synthetic peptides (Ala-Leu, Glu-Lys, Phe-Phe, 222 
His-Leu, Phe-Leu, Leu-Leu/Ile-Leu/Leu-Ile/Ile-Ile, Leu-Pro-Leu, Pro-Pro, Ser-Leu, Val-Pro, 223 
Trp-Lys, Trp-Gln, Trp-Ile, Trp-Leu, Trp-Tyr, Tyr-Leu, Tyr-Ile, Tyr-Pro) were analysed using the 224 
same LC-MS/MS conditions in order to confirm the software identification. All other amino acid 225 
sequences detected using PEAKS Studio software were manually checked to verify that the 226 
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peptide sequence is present in the main milk proteins and to confirm the peptide’s fragmentation 227 
data (as ion series continuity and major peaks identified as b or y ions). The peptides identified in  228 
H9, H16, H17, SGID_H9 and SGID_CM milk were compared for similarity with previously 229 
published DPP-IV inhibitory sequences. 230 
2.10 Statistical analysis  231 
A one-way analysis of variance (ANOVA) at a significance level of p < 0.05 was employed to 232 
study differences between mean DH and DPP-IV IC50 values. ANOVA was followed by a post-233 
hoc Student Newman Keuls test (p < 0.05) conducted with SPSS (version 22, SPSS Inc., 234 
Chicago, IL, USA). The lack of significant difference between experimental and predicted DPP-235 
IV IC50 values of H16 was assessed with a one-sample Student test (t-test, p < 0.05) using 236 
Matlab. 237 
3 Results and Discussion 238 
3.1 In silico analysis of camel milk proteins 239 
Several known unique DPP-IV inhibitory peptide sequences were identified within camel and 240 
bovine milk proteins (Table 2) following in silico analysis. The number of known DPP-IV 241 
inhibitory peptide sequences varied between 7 (-La) and 25 (-CN) for individual camel milk 242 
proteins and between 16 ((s2-CN/-La) and 40 (-CN) peptides for bovine milk proteins. The 243 
PC and PCcorrected for camel milk proteins varied between 18.5 (s2-CN) and 36.4% (-CN), and 244 
11.4 (-La) and 32.7% (-CN), respectively. While for bovine proteins, the PC and PCcorrected 245 
varied between 19.3 (s2-CN) and 51.2% (-La), and 15.9 (s2-CN) and 35.8% (-La), 246 
respectively. The DPP-IV PI for camel and bovine milk proteins ranged from 4.2 10-6 (-La) 247 
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and 10.0 10-6 (-CN), and 3.2 10-6 (s2-CN) and 22.4 10
-6
 (κ-CN) µM-1 g-1, respectively. The 248 
predicted DPP-IV PI of camel milk proteins was lower than that of the corresponding bovine 249 
milk proteins for s1-CN, κ-CN and -La. However, for s2-CN and -CN a higher DPP-IV PI 250 
was found for camel compared to bovine milk (Table 2). 251 
Previous in silico analyses of individual bovine milk proteins predicted that both CNs and whey 252 
proteins contain relatively potent DPP-IV inhibitory peptides (Lacroix & Li-Chan, 2012b; 253 
Nongonierma & FitzGerald, 2014a). The differences between camel and bovine milk proteins 254 
arise from the fact that the amino acid sequences of their individual proteins differ. The 255 
homology between bovine and camel milk proteins, as determined using a basic local alignment 256 
search tool (BLAST) analysis (http://www.uniprot.org/blast/), was found to be of 46.6, 58.3, 257 
69.3, 58.9, 69.7% for αs1-CN, αs2-CN, β-CN, κ-CN and -La, respectively. This can explain 258 
differences in DPP-IV inhibitory peptides found within individual proteins from camel and 259 
bovine milks (Table 2). In addition, the majority of the DPP-IV inhibitory peptide sequences 260 
appear to have been identified within bovine milk proteins (Lacroix & Li-Chan, 2016). However, 261 
no DPP-IV inhibitory peptide sequences have been identified to date within a DPP-IV inhibitory 262 
camel milk protein hydrolysate. The particularly high DPP-IV PI of bovine κ-CN is attributed to 263 
the presence of Ile-Pro-Ile (κ-CN (f26-28)), which is the most potent DPP-IV inhibitory peptide 264 
identified to date (Umezawa et al., 1984). Results from the in silico analysis strongly suggest that 265 
camel milk proteins may be used as starting substrates for the generation of hydrolysates 266 
displaying high inhibition of DPP-IV. 267 
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3.2 Physicochemical characteristics of the camel milk protein hydrolysates generated 268 
within the DOE 269 
The protein content of the defatted freeze-dried camel milk was 19.7  1.3 % (w/w). This value 270 
is of the same order as those previously reported (~ 25 % (w/w)) in the literature (Hailu et al., 271 
2016; Khan & Iqbal, 2001). 272 
The DH values of the 15 hydrolysates (H1-H15) generated within the DOE are listed in Table 1. 273 
The DH of the three independent replicates of the central point H12A, H12B and H12C were 274 
significantly different (p < 0.05), although they were of the same order. The DH of the 15 275 
hydrolysates ranged from 5.66  0.21 (H1) to 28.84  0.35 % (H5, Table 1). 276 
The molecular mass distribution of the hydrolysates H1-H15 is shown in Fig. 1A. While all 277 
hydrolysates still contained unhydrolysed proteins (> 10 kDa), significant protein breakdown 278 
was seen compared to unhydrolysed camel milk proteins. H9 contained the highest proportion of 279 
peptides ( 5 kDa) and H2 the lowest. The RP-UPLC profile of H9 is shown in Fig. 1B. No 280 
intact protein (retention time > 25 min) could be seen in the peptide profile of H9. Different 281 
peptide peaks were seen to have eluted throughout the chromatogram, indicating that this sample 282 
contained peptides having a wide range of hydrophobicities. 283 
3.3 DPP-IV inhibition of the camel milk protein hydrolysates generated within the DOE 284 
(H1-H15) 285 
Intact camel milk proteins did not inhibit DPP-IV. The DPP-IV IC50 values of the 15 286 
hydrolysates (H1-H15) are provided in Table 1. Generation of the camel milk protein 287 
hydrolysates is reproducible from a DPP-IV inhibitory property point of view as indicated by the 288 
lack of significant differences (p > 0.05) between the DPP-IV IC50 values of three independent 289 
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replicates of the central point H12A, H12B and H12C (Table 1). While some differences were 290 
seen in the DH of these hydrolysates, this did not appear to impact on the bioactivity. 291 
The DPP-IV IC50 values of the 15 hydrolysates H1-H15 vary between 0.52  0.06 (H9) and 1.26 292 
 0.13 (H1) mg mL-1 (Table 1). Some of the hydrolysates generated herein with camel milk 293 
exhibit lower DPP-IV IC50 values than those reported in the literature with bovine whey proteins 294 
and CNs (Nongonierma & FitzGerald, 2013a; Power, Fernández, Norris, Riera, & FitzGerald, 295 
2014; Silveira, Martínez-Maqueda, Recio, & Hernández-Ledesma, 2013) or caprine CNs (Zhang 296 
et al., 2016) hydrolysed with trypsin. Bovine whey protein concentrate (WPC) hydrolysed with 297 
trypsin had a DPP-IV IC50 value of 1.51 mg mL
-1
 (Silveira et al., 2013). DPP-IV IC50 values of 298 
1.00 and 1.11 mg mL
-1
 were reported for bovine whey protein isolate (WPI) and CN 299 
hydrolysates generated with trypsin, respectively (Nongonierma & FitzGerald, 2013a). A tryptic 300 
hydrolysate of -Lg was found to have a DPP-IV IC50 value of 1.6 mg mL
-1
 (Power et al., 2014). 301 
DPP-IV IC50 values of 0.80 and 0.89 mg mL
-1
 were described for tryptic hydrolysates of caprine 302 
and bovine CN, respectively (Zhang et al., 2016). To our knowledge, studies which have 303 
evaluated the DPP-IV inhibitory properties of substrates having the same protein composition as 304 
native camel milk do not appear in the current literature. The DPP-IV IC50 values of hydrolysates 305 
H1-H15 were comparable to those obtained with bovine MPI hydrolysates also generated with 306 
the same trypsin preparation and a DOE which varied between 0.68 ± 0.06 and 1.37 ± 0.20 mg 307 
mL
-1
 (Nongonierma, Mazzocchi, et al., 2017). 308 
3.4 Effect of the parameters of the DOE on DPP-IV inhibitory properties of camel milk 309 
protein hydrolysates and RSM 310 
The lack of fit for the complete and simplified models (p > 0.05) showed that they had good 311 
predictive ability. All three parameters of the DOE (temperature, E:S ratio and time) had a 312 
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significant effect (p < 0.05) on the DPP-IV IC50 value both in the complete and simplified 313 
models. In addition, two interactions, E:S
2
 and T×ES were also significant in both models (p < 314 
0.05, Table 3). As indicated by the negative coefficients associated with E:S and time (Table 3), 315 
an increase in both parameters results in a decrease in DPP-IV IC50 value. In contrast, the 316 
positive coefficient associated with temperature indicated that a decrease in incubation 317 
temperature would yield a decrease in DPP-IV IC50 value. The complete model gave a higher 318 
correlation between the predicted and experimental DPP-IV IC50 values (Table 3 and 319 
Supplementary Fig. S1). Therefore, the coefficients of the complete model described in Equation 320 
2 (Table 3) were used to plot the RSM profiles, which are illustrated in Fig. 2. The effect of 321 
temperature, E:S and time can be visualised on the RSM profiles where the DPP-IV IC50 values 322 
are lowest when E:S or time are at the high level (+1, Fig. 2A-2C) and the temperature is at the 323 
low level (-1, Fig. 2A and 2B). 324 
To test the models, hydrolysis conditions (40C, 1.8% E:S and 218 min) predicted to yield a low 325 
DPP-IV IC50 value (0.50 mg mL
-1
 both with the complete and simplified models), within the 326 
DOE boundaries were investigated. The DH of three replicates of H16 presented some variability 327 
(p < 0.05), however, this did not appear to significantly impact their DPP-IV inhibitory potency 328 
(p > 0.05, Table 1). The average DPP-IV IC50 value obtained with all three hydrolysates (H16A, 329 
H16B and H16C, Table 1) was of 0.68 ± 0.08 mg mL
-1
. Generation of H16 in triplicate yielded 330 
hydrolysates with the same DPP-IV IC50 value (p > 0.05, Table 1). The average DPP-IV IC50 331 
value of H16 was significantly higher than that of the predicted value (p < 0.05, and Table 1 and 332 
Supplementary Fig. S1). 333 
Several studies have used multifactorial DOE and RSM to predict the optimum hydrolysis 334 
parameters for the release of bioactive peptides from bovine milk proteins (Contreras et al., 335 
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2011; Naik, Mann, Bajaj, Sangwan, & Sharma, 2013; Nongonierma, Le Maux, et al., 2017; van 336 
der Ven et al., 2002). To the best of our knowledge, this process has not been applied to camel 337 
milk proteins for the study of bioactive peptides. In agreement with previous studies, it was also 338 
shown that temperature, E:S and time can modify the release of bioactive peptides during 339 
enzymatic hydrolysis (Contreras et al., 2011; Naik et al., 2013; van der Ven et al., 2002). The 340 
results herein are in contrast with these found during bovine MPI hydrolysis using a similar 341 
DOE, which showed an effect of E:S and time and no effect of temperature on the DPP-IV 342 
inhibitory potency of the resultant hydrolysates (Nongonierma, Mazzocchi, et al., 2017). These 343 
results may arise from compositional and structural differences between camel and bovine milk 344 
protein substrates. 345 
The DOE allowed the identification of hydrolysis conditions yielding relatively low DPP-IV IC50 346 
values when compared to the literature, as discussed earlier (section 3.3.). While significant 347 
differences were observed between the predicted and experimental DPP-IV inhibitory potencies 348 
of H16, both DPP-IV IC50 values were of the same order, i.e., between 0.5-0.7 mg mL
-1
. This 349 
may indicate that within the DOE boundaries, these values were within the lowest values which 350 
could be achieved. A similar trend has been observed during hydrolysis of bovine MPI in an 351 
earlier study, which was explained by the fact that the substrate may become limiting for the 352 
release of additional DPP-IV inhibitory peptides (Nongonierma, Mazzocchi, et al., 2017). 353 
Product-type inhibition has also been reported with trypsin and chymotrypsin during hydrolysis 354 
reactions (Iametti et al., 2002). Another possibility is that potent DPP-IV inhibitory peptides may 355 
have been further degraded during hydrolysis as was demonstrated earlier in the case of His-Leu-356 
Pro-Leu-Pro (-CN (f134-138)), an ACE inhibitory peptide (Quirós, Hernández-Ledesma, 357 
Ramos, Martín-Álvarez, & Recio, 2012). 358 
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3.5 Comparison of camel milk protein and bovine MPI hydrolysates 359 
Bovine MPI was hydrolysed (H17A, H17B and H17C) using the same conditions as those 360 
employed for camel milk to generate H16 (i.e., 40C, 1.8% E:S and 218 min). The DH of 361 
hydrolysates (H16 and H17) obtained with camel and bovine milk using the same hydrolytic 362 
conditions varied between 12-15% (Table 1). Hydrolysis of bovine MPI resulted in a significant 363 
protein breakdown as evidenced by the decreased proportion of the protein fraction (> 10 kDa) 364 
from 96.8 to 0.4% in MPI and H17, respectively. Overall, H17 hydrolysates contained less intact 365 
proteins and more peptides < 5 kDa than H16 (Fig. 1A). Interestingly, the average DPP-IV IC50 366 
value of H17 was 0.85 ± 0.10 mg mL
-1
, which was significantly higher (p < 0.05) than that of 367 
H16 (Table 1). This result is in agreement with the in silico analysis, which concluded that a 368 
higher DPP-IV PI for -CN, the major milk protein, would be observed when it originated from 369 
camel compared to bovine milk proteins (Table 2). This is particularly relevant since the 370 
concentration of -CN is higher in camel than in bovine milk, i.e., 15.6 vs. 9.8 g L-1 (Hailu et al., 371 
2016) and this protein is likely to contribute to a major extent to the overall DPP-IV inhibitory 372 
properties of the milk protein hydrolysates. Previous studies have compared CNs originating 373 
from caprine and bovine milk. It was shown that a trypsin hydrolysate of caprine CNs was a 374 
more potent DPP-IV inhibitor than the equivalent bovine CN hydrolysate (Zhang et al., 2016). In 375 
the previous study, there was also an agreement between the in silico and in vitro analyses, 376 
showing a higher DPP-IV PI for caprine compared to bovine CNs. Camel milk proteins 377 
hydrolysed with trypsin, using the same hydrolysis conditions, appear to yield more potent DPP-378 
IV inhibitory hydrolysates than bovine milk. This suggests that camel milk hydrolysates may be 379 
of interest for the regulation of serum glucose in humans. 380 
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Differences in the composition (amino acid sequence and concentration) of camel and bovine 381 
milk proteins may also affect their digestibility. Salami et al. (2008) have studied the digestion of 382 
camel and bovine whey proteins and CNs with intestinal enzymes (i.e., trypsin and 383 
chymotrypsin). The whey proteins from camel milk were digested to a lower extent by trypsin 384 
and chymotrypsin compared to the bovine whey proteins. On the other hand, digestion of CNs 385 
with a trypsin/chymotrypsin mixture was more extensive in camel milk than in bovine milk.A 386 
higher digestibility of camel compared to bovine milk proteins has recently been reported using 387 
an in vitro SGID protocol (Tagliazucchi, Shamsia, & Conte, 2016). Differences in the digestion 388 
of camel and bovine milks may affect the kinetics of release of DPP-IV inhibitory peptides in 389 
vivo. Studies on the kinetics of release of DPP-IV inhibitory peptides following ingestion of 390 
camel and bovine milks are warranted in order to better understand their potential antidiabetic 391 
effects in vivo. 392 
3.6 Simulated gastrointestinal digestion of intact and hydrolysed camel milk 393 
The most potent hydrolysate generated within the DOE (H9) and camel milk were subjected to 394 
SGID. The proportion of low molecular mass components (< 5 kDa) found within SGID_H9, H9 395 
and SGID_CM was 99, 97 and 94%, respectively (Fig. 1A). The peptide profiles of SGID_H9 396 
and H9 differed, showing peaks eluting at different times while SGID_H9 and SGID_CM had 397 
similar peptide profiles (Fig. 1B). The DPP-IV IC50 value of SGID_H9 was not significantly 398 
different from that of H9 (0.58  0.05 vs. 0.52  0.06 mg mL-1, p > 0.05, Table 1), suggesting 399 
that the differences in peptide profiles did not reflect in the DPP-IV IC50 values. The SGID_CM 400 
hydrolysate yielded a low DPP-IV IC50 value (0.70  0.13 mg mL
-1
). This value was 401 
significantly higher (p < 0.05) than that of H9 and of the same order as that of SGID_H9 (p > 402 
0.05, Table 1). 403 
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Other studies have shown that following SGID of intact bovine milk proteins, an increased DPP-404 
IV inhibition in the digests could be observed (Lacroix & Li-Chan, 2012a; Nongonierma, 405 
Mazzocchi, et al., 2017; Tulipano, Faggi, Nardone, Cocchi, & Caroli, 2015). On the other hand, 406 
the DPP-IV inhibitory potency of bovine milk protein hydrolysates was shown to remain the 407 
same, decrease or increase following SGID (Nongonierma & FitzGerald, 2013b; Nongonierma, 408 
Mazzocchi, et al., 2017; Power-Grant et al., 2015). It can be concluded that the impact of SGID 409 
of the hydrolysates on the DPP-IV inhibitory potency depends on the peptides present within the 410 
hydrolysates and their susceptibility to gastrointestinal enzyme activities. Overall, SGID_H9 and 411 
SGID_CM yielded relatively potent DPP-IV inhibitory samples, which make them interesting for 412 
further in vivo studies. In fact several studies have shown that bovine milk protein hydrolysates, 413 
having a lower DPP-IV inhibitory potency than H9, induced an antidiabetic activity in small 414 
animals (Hsieh et al., 2016; Uchida, Ohshiba, & Mogami, 2011; Uenishi, Kabuki, Seto, 415 
Serizawa, & Nakajima, 2012), indicating a greater antidiabetic potential for camel milk 416 
hydrolysates. 417 
3.7 DPP-IV inhibitory peptide identification 418 
Known DPP-IV inhibitory peptides identified within H9, H16 and H17 are listed in Table 4. A 419 
range of known DPP-IV inhibitory peptides were identified across the samples, which had 2-11 420 
amino acid residues in length. All DPP-IV inhibitory peptides identified in H9 were also present 421 
in H16, which may partly explain their similar DPP-IV inhibitory potency (Table 1). Camel milk 422 
protein hydrolysates contained relatively potent DPP-IV inhibitory peptides such as Trp-Lys and 423 
Leu-Pro-Val-Pro-Gln, having previously been reported to have DPP-IV IC50 values of 40.6 424 
(Nongonierma & FitzGerald, 2013c) and 43.69 µM (Nongonierma & FitzGerald, 2016), 425 
respectively. 426 
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In agreement with their protein composition, differences in the DPP-IV inhibitory peptides of 427 
camel (H16) and bovine (H17) milk protein hydrolysates were detected. For example, the most 428 
potent DPP-IV inhibitors identified in H17 were Ile-Asn-Asn-Gln-Phe-Leu-Pro-Tyr-Pro-Tyr, 429 
Trp-Leu and Ile-Pro-Ala-Val-Phe with DPP-IV IC50 values of 40.1 (Zhang, Chen, Ma, & Chen, 430 
2015), 43.6 (Nongonierma & FitzGerald, 2013c) and 44.7 µM (Silveira et al., 2013), 431 
respectively. Interestingly, several of these peptides have been also identified within 432 
hydrolysates of bovine (Silveira et al., 2013) and caprine (Zhang et al., 2015) milk protein 433 
hydrolysates generated with intestinal enzymes (i.e., Corolase PP and trypsin, respectively). The 434 
trypsin preparation (PTN 6.0S) employed during the hydrolysate generation herein has also been 435 
reported to contain chymotrypsin activity (Novozymes). Trypsin and chymotrypsin preferentially 436 
cleave peptide bonds at the C-terminal side of Arg/Lys and bulky hydrophobic amino acids (i.e., 437 
Tyr, Trp, Phe and Lys), respectively (Godfrey, 1996). This is in agreement with the fact that 438 
many peptides within H9, H16 and H17 possess C-terminal Lys, Tyr and Phe residues (Table 4). 439 
The known DPP-IV inhibitory peptides identified in SGID_H9 and SGID_CM are also listed in 440 
Table 4. All the DPP-IV inhibitory peptides identified within H9 were also present in SGID_H9. 441 
This may partly explain the fact that both samples gave similar DPP-IV IC50 values (Table 1). 442 
All peptides identified in SGID_CM were also found within SGID_H9. Interestingly, the most 443 
potent DPP-IV inhibitors (Leu-Pro-Val-Pro-Gln and Trp-Lys) identified within the camel milk 444 
protein hydrolysates were also found within SGID_H9 and SGID_CM. Other peptides present 445 
within the hydrolysates may also contribute to their DPP-IV inhibition. Future work may include 446 
bioassay-driven fractionation followed by confirmatory studies with synthetic peptides as well as 447 
peptide quantification to evaluate other DPP-IV inhibitory peptides potentially present within the 448 
hydrolysates. 449 
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4 Conclusions 450 
In this study, it was demonstrated for the first time that camel milk proteins constitute an 451 
interesting source of DPP-IV inhibitory peptides by using an in silico analysis approach. In 452 
addition, hydrolysis of camel milk proteins with trypsin allowed the generation of relatively 453 
potent DPP-IV inhibitory hydrolysates. Using the same hydrolytic conditions, a more potent 454 
DPP-IV inhibitory hydrolysate was generated with camel compared with bovine milk. 455 
Compositional differences in their constitutive proteins may be responsible for these results, 456 
which were further confirmed by the identification of different DPP-IV inhibitory peptides 457 
within both hydrolysates. Two potent DPP-IV inhibitory peptides identified within camel milk 458 
protein hydrolysates were also identified within SGID_ H9 and SGID_CM, suggesting (1) the 459 
potential to release these peptides during the digestion of camel milk and (2) the stability of these 460 
peptides to digestive enzymes. Future work may involve investigation other enzyme activities 461 
and hydrolytic conditions which may allow the generation of more potent DPP-IV inhibitory 462 
camel milk protein hydrolysates. 463 
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Table 1. Dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) of camel milk protein hydrolysates generated within the 
experimental design (H1-H15), cross-validation camel milk protein hydrolysate (H16), bovine milk protein isolate (MPI) hydrolysed using the same 














) Temperature (°C) E:S (%) Time (min) 
H1 camel 60 (+1.00) 0.50 (-1.00) 60 (-1.00) 5.66  0.21a 1.26  0.13k 
H2 camel 60 (+1.00) 0.50 (-1.00) 240 (+1.00) 6.97  0.08b 1.12  0.14i 
H3 camel 60 (+1.00) 2.00 (+1.00) 60 (-1.00) 10.09  0.38d 0.72  0.11e,f,g 
H4 camel 60 (+1.00) 2.00 (+1.00) 240 (+1.00) 13.24  0.62f,g,h 0.67  0.09b,c,d,e,f 
H5 camel 60 (+1.00) 1.25 (0.00) 150 (0.00) 28.84  0.35n 0.73  0.13c,d,e,f,g 
H6 camel 40 (-1.00) 0.50 (-1.00) 60 (-1.00) 8.48  1.18c 1.07  0.14i,j 
H7 camel 40 (-1.00) 0.50 (-1.00) 240 (+1.00) 13.37  0.24f,g,h 0.75  0.09d,e,f,g 
H8 camel 40 (-1.00) 2.00 (+1.00) 60 (-1.00) 16.08  0.77j,k 0.70  0.10b,c,d,e,f 
H9 camel 40 (-1.00) 2.00 (+1.00) 240 (+1.00) 19.98  0.34m 0.52  0.06a 
H10 camel 40 (-1.00) 1.25 (0.00) 150 (0.00) 15.92  0.24j,k 0.61  0.03a,b,c,d 
H11 camel 50 (0.00) 1.25 (0.00) 60 (-1.00) 12.59  0.66f,g 0.74  0.05d,e,f,g 
H12A camel 50 (0.00) 1.25 (0.00) 150 (0.00) 15.55  1.19j,k 0.67  0.08b,c,d,e,f 
H12B camel 50 (0.00) 1.25 (0.00) 150 (0.00) 13.07  0.53f,g,h 0.73  0.07c,d,e,f,,g 
H12C camel 50 (0.00) 1.25 (0.00) 150 (0.00) 13.19  0.34f,g,h 0.70  0.05b,c,d,e,f, 
H13 camel 60 (+1.00) 0.50 (-1.00) 240 (+1.00) 11.05  1.11e 0.97  0.10g,h 
H14 camel 40 (-1.00) 2.00 (+1.00) 240 (+1.00) 16.10  0.22j,k 0.63  0.08a,b,c,d,e 
 29 
H15 camel 50 (0.00) 1.25 (0.00) 240 (+1.00) 16.79  0.38l 0.58  0.12a,b 
H16A camel 40 (-1.00) 1.8 (0.66) 217.5 (0.70) 13.75  0.18h,i 0.66  0.08b,c,d,e,f 
H16B camel 40 (-1.00) 1.8 (0.66) 217.5 (0.70) 12.29  0.18f 0.72  0.10b,c,d,e,f 
H16C camel 40 (-1.00) 1.8 (0.66) 217.5 (0.70) 15.01  0.47i,j 0.66 0.06b,c,d,e,f 
H17A bovine 40 (-1.00) 1.8 (0.66) 217.5 (0.70) 13.44  0.37f,g,h 0.87  0.12g,h 
H17B bovine 40 (-1.00) 1.8 (0.66) 217.5 (0.70) 14.33 0.07g,h 0.86  0.05g,h 
H17C bovine 40 (-1.00) 1.8 (0.66) 217.5 (0.70) 14.39  0.24h,i 0.82  0.05f,g 
SGID_H9 camel - - - nd 0.58  0.05a,b,c 
SGID_CM camel - - - nd 0.70  0.13b,c,d,e,f 
1
The z-centred values for each variable of the experimental design are provided in brackets. 
2
Mean  SD (n=3). Within the same column, values with different superscript letters are significantly different (p < 0.05). IC50: concentration inducing 50% DPP-IV inhibition, 
expressed in mg protein equivalent per mL (mg mL
-1
). The IC50 value of the positive control Ile-Pro-Ile was 3.44 ± 0.36 µM. 
nd: not determined.  
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Table 2. Predicted dipeptidyl peptidase IV (DPP-IV) inhibitory potential of major camel (Camelus dromedarius) and bovine (Bos taurus) milk 
proteins. Different parameters determined by the in silico prediction approach include the sequence of the DPP-IV inhibitory peptides identified 
within the protein, protein coverage (PC), corrected PC (PCcorrected) taking into account the peptides considered in the in silico model, and the DPP-IV 










DPP-IV inhibitory peptide sequences
3








Camel αs1-CN 5.3 FF, FP, HL, HP, IA, IL, IP, LA, LL, MP, NH, RP, 
VA, VL, WW, WY, YI, YL, YP 
19 24.2 23.3 4.7 
 αs2-CN 2.3 AL, FL, HP, IP, LW, NH, VA, VP, VR, WK, WN, 
WP, YL, YP 
14 18.5 18.0 5.2 
 β-CN 15.6 AL, FL, FLQP, FP, HL, HP, IA, IL, IP, LL, LP, 
LPL, LPLPL, LPLPLL, LPP, LPQ, LPVPQ, LQP, 
MP, PPL, TH, VL, VP, VR, YP 
25 36.4 32.7 10.0 
 κ-CN 0.8 AL, FP, IA, IP, LA, LL, LP, RP, VA, VP, YP 11 22.8 22.2 5.4 
 β-Lg 0.0 - - - - - 
 α-La 2.3 FL, IL, LA, WC, WI, WL, WQ 7 24.1 11.4 4.2 
Bovine αs1-CN 9.5 FF, FP, HP, IP, LA, LL, LP, LPQ, LW, MP, RP, VA, 
VL, VP, VPL, WY, YL, YP 
18 24.1 24.1 8.0 
 αs2-CN 2.5 AL, FA, FL, FP, IP, LP, LPQ, VA, VL, VP, VPITPT, 
VPITPTL, VR, WI, WIQP, YL 
16 19.3 15.9 3.2 
 β-CN 9.8 FA, FL, FLQP, FP, FPGPIPN, GPV, HL, HP, IP, 
IPPL, IPPLTQT, IPPLTQTPV, LL, LP, LPL, LPLPL, 
40 45.9 30.6 7.6 
 31 
LPLPLL, LPP, LPQ, LPQNIPP, LPQNIPPL, 
LPQNIPPLT, LPVPQ, LQP, MP, PPL, PQNIPPL, 
QPHQPLPPT, QPLPPT, TPVVVPP, VL, VLGP, VP, 
VPGEIVE, VR, WM, YP, YPFPGP, YPFPGPIPN, 
YPVEPF 
 κ-CN 3.3 AL, FF, FL, HL, HP, IA, IL, INNQFLPYPY, IP, IPI, 
IPIQY, LP, LPYPY, VA, VL, VP, VR, WQ, YI, YP, 
YPY, YPYY 
22 30.8 27.8 22.4 
 β-Lg 3.1 AL, IA, IL, IP, IPA, IPAVF, IPAVFK, IPAVFKIDA, 
IQKVAGTW, LA, LKALPMH, LKPTPEGDL, 
LKPTPEGDLE, LKPTPEGDLEIL, LL, LP, 
TPEVDDEALEK, TW, VA, VAGTWY, VL, 
VLDTDY, VLVLDTDYK, VR, WY, YL 
26 45.1 32.7 7.9 
 α-La 1.1 AL, FL, IL, ILDKVGINY, IVQNNDSTEYGLF, LA, 
LAHKALCSEKL, LCSEKLDQ, LKGYGGVSLPE, 
LP, TKCEVFRE, WC, WL, WLAHKAL, 
WLAHKALCSEKLDQ, WV 
16 51.2 35.8 5.8 
1α-La: α-lactalbumin; β-Lg: β-lactoglobulin ; CN: casein. 
2
Individual protein concentrations are taken from Hailu et al. (2016) 
3
Peptide sequences in bold are found within the same individual proteins in both the bovine and camel species. 
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Table 3. Coefficients of the multilinear regression (MLR) model correlating the dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory 
concentration (IC50) of the camel milk protein hydrolysates to the parameters of the design of experiment (DOE) and their interactions. 






Standard Error t value p
2
 
Complete Intercept 0.67 0.02 36.64 2.93E-09 
ES  -0.19 0.01 -13.70 2.60E-06 
T 0.09 0.01 6.75 2.66E-04 
t -0.09 0.01 -6.64 2.94E-04 
ES² 0.15 0.03 5.80 6.65E-04 
T² 0.02 0.03 0.89 0.40 
t² 0.01 0.03 0.37 0.73 
T×ES -0.04 0.02 -2.68 0.03 
ES×t  0.02 0.02 1.38 0.21 
T×t 0.03 0.02 2.02 0.08 
Root mean squared error = 0.0428; R
2
 = 0.981; p-value model = 3.5E-05; p-value lack of fit = 0.342 
Optimised Intercept 0.68 0.02 36.95 6.89E-13 
ES  -0.19 0.02 -12.04 1.13E-07 
T 0.09 0.02 5.93 9.93E-05 
t -0.09 0.02 -5.83 1.14E-04 
ES
2
 0.17 0.02 7.02 2.22E-05 
T×ES -0.04 0.02 -2.35 3.85E-02 
Root mean squared error = 0.0487; R
2
 = 0.961; p-value model = 2.33E-07; p-value lack of fit = 0.299 
1
T: temperature; ES: enzyme to substrate ratio and t: time. 
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2
Coefficients of the parameters
 
having a p < 0.05 are significantly different from 0. 
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Table 4. Dipeptidyl peptidase IV (DPP-IV) inhibitory peptide sequences detected by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) in camel (C; H9 and H16) and bovine (B; H17) milk protein hydrolysates and the simulated 
gastrointestinal digestion (SGID) of H9 (SGID_H9) and camel milk (SGID_CM). 










H9 H16 H17 SGID_H9 SGID_CM 
AL diverse nd nd    882.1 (Nongonierma & FitzGerald, 2013a) 
EK diverse      3216.75 (Nongonierma & FitzGerald, 2013a) 
FF diverse      546.84 (Neves, Harnedy, O’Keeffe, & 
FitzGerald, 2017) 
FL diverse      399.6 (Nongonierma & FitzGerald, 2013a) 
HL diverse nd nd    143.2 (Nongonierma & FitzGerald, 2013a) 
ILDKVGINY B -La (f95-
103) 
nd nd  nd nd 263 (Lacroix & Li-Chan, 2014) 
INNQFLPYPY B κ-CN (f51-
60) 
nd nd  nd nd 40.08 (Zhang et al., 2015) 
IPAVF B -Lg (f79-
82) 
nd nd  nd nd 44.7 (Silveira et al., 2013) 
IPAVFK B -Lg (f79-
83) 
nd nd  nd nd 143 (Silveira et al., 2013) 
LA diverse   nd   91; 300 (Lan et al., 2015; Tulipano et al., 2012) 
LL diverse      191.7 (Connolly, O'Keeffe, Nongonierma, 
Piggott, & FitzGerald, 2017) 
LPL B -CN (f135-
137) 
nd nd  nd nd 241.4 (Nongonierma & FitzGerald, 2014b) 
LPLPL C -CN (f136-
140) 
  nd  nd 325 (Nongonierma & FitzGerald, 2014b) 
LPVPQ C -CN (f172-
177) 
  nd   43.69 (Nongonierma & FitzGerald, 2016) 
 35 
PP diverse      4343.48; 
5860 
(Hatanaka et al., 2012; Neves et al., 
2017) 
SL diverse      2517.08 (Nongonierma & FitzGerald, 2013a) 
TPEVDDEALEK B -Lg (f125-
135) 
nd nd  nd nd 319.5; 587.7 (Power et al., 2014; Silveira et al., 
2013) 
VAGTWY B -Lg (f15-
20) 
nd nd  nd nd 174 (Uchida et al., 2011) 
VLVLDTDYK B -Lg (f92-
100) 
nd nd  nd nd 424.4 (Silveira et al., 2013) 
WK C s2-CN (f69-
70) 
  nd   40.6 (Nongonierma & FitzGerald, 2013c) 
WL diverse nd nd   nd 43.6 (Nongonierma & FitzGerald, 2013c) 
WY diverse nd nd  nd nd 281 (Nongonierma & FitzGerald, 2013c) 
YL diverse      940.2 (Le Maux, Nongonierma, Murray, 
Kelly, & FitzGerald, 2015) 
YP diverse      658.1; 
7564.02; 
3170 
(Hatanaka et al., 2012; Neves et al., 
2017; Nongonierma & FitzGerald, 
2014b) 
YPVEPF B -CN (f114-
120) 
nd nd  nd nd 124.7 (Nongonierma & FitzGerald, 2016) 
1α-La: α-lactalbumin; β-Lg: β-lactoglobulin; B: bovine; C: camel; CN: casein. Diverse: peptide sequence detected within diverse individual milk 
proteins. 
2: peptide sequence detected within the sample; nd: not detected  




Figure 1. (A) Molecular mass distribution profile of camel milk protein hydrolysates generated 
within the experimental design (H1-H15), cross-validation camel milk (CM) protein hydrolysate 
(H16), bovine milk protein isolate (MPI) hydrolysed with the same conditions as H16 (H17), and 
the simulated gastrointestinal digest (SGID) of H9 (SGID_H9) and of camel milk (SGID_CM). 
(B) Reverse-phase ultra-performance liquid-chromatography (RP-UPLC) profile of CM, 
SGID_CM, SGID_H9 and H9. 
 
Figure 2. Response surface methodology (RSM) curves of the dipeptidyl peptidase IV (DPP-IV) 
half maximal inhibitory concentration (IC50) as a function of the temperature (Temp), time and 
enzyme to substrate ratio (ES). The curves were constructed at the central condition (0) of the 














































Supplementary Figure S1. Predicted dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) obtained with 
(A) the complete and (B) the simplified models as a function of the experimental DPP-IV IC50 values of hydrolysates H1-H16. H16 is 
the external validation sample (generated at 40C, 1.8% E:S and 218 min). Curves were plotted with Microsoft Excel 2010 (Microsoft 
Corporation, Redmond, WA, USA) using the models described in Equation 2 and Table 1. 
 
